InvestorsHub Logo
Followers 253
Posts 17936
Boards Moderated 0
Alias Born 01/19/2006

Re: None

Wednesday, 12/11/2019 2:49:15 PM

Wednesday, December 11, 2019 2:49:15 PM

Post# of 54985
There is potential competition for XX11 in reducing smoking, or cessation thereof:

News: $ACHV Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

SEATTLE and VANCOUVER, British Columbia , Dec. 9, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today ...

ACHV - Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

https://marketwirenews.com/news-releases/achieve-life-sciences-announces-completion-of-meetin-7173828705760771.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XXII News